Management of glioblastoma: State of the art and future directions

AC Tan, DM Ashley, GY López… - CA: a cancer journal …, 2020 - Wiley Online Library
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

[HTML][HTML] Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review

N Singh, A Miner, L Hennis, S Mittal - Cancer drug resistance, 2021 - ncbi.nlm.nih.gov
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Frontiers in the treatment of glioblastoma: Past, present and emerging

TI Janjua, P Rewatkar, A Ahmed-Cox, I Saeed… - Advanced drug delivery …, 2021 - Elsevier
Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive
research over the last several decades, the survival rates for GBM have not improved and …

[HTML][HTML] m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells

QI Cui, H Shi, P Ye, L Li, Q Qu, G Sun, G Sun, Z Lu… - Cell reports, 2017 - cell.com
RNA modifications play critical roles in important biological processes. However, the
functions of N 6-methyladenosine (m 6 A) mRNA modification in cancer biology and cancer …

[HTML][HTML] Glioblastoma: overview of disease and treatment

ME Davis - Clinical journal of oncology nursing, 2016 - ncbi.nlm.nih.gov
Background Glioblastoma (GBM) is the most common and aggressive malignant brain tumor
in adults. Current treatment options at diagnosis are multimodal and include surgical …

Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians

JT Low, QT Ostrom, G Cioffi, C Neff… - Neuro-oncology …, 2022 - academic.oup.com
Abstract Background The Central Brain Tumor Registry of the United States (CBTRUS)
contains information on all primary brain and other central nervous system (CNS) tumors …

[HTML][HTML] N6-methyladenosine links RNA metabolism to cancer progression

D Dai, H Wang, L Zhu, H Jin, X Wang - Cell death & disease, 2018 - nature.com
Abstract N6-methyladenosine (m6A) is the most abundant mRNA modification. With the
development of antibody-based sequencing technologies and the findings of m6A-related …

Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis

Q Cui, K Yin, X Zhang, P Ye, X Chen, J Chao, H Meng… - Nature cancer, 2021 - nature.com
Pseudouridine is the most frequent epitranscriptomic modification. However, its cellular
functions remain largely unknown. Here, we show that pseudouridine synthase 7 (PUS7) is …

[HTML][HTML] Convolutional neural network techniques for brain tumor classification (from 2015 to 2022): Review, challenges, and future perspectives

Y Xie, F Zaccagna, L Rundo, C Testa, R Agati, R Lodi… - Diagnostics, 2022 - mdpi.com
Convolutional neural networks (CNNs) constitute a widely used deep learning approach that
has frequently been applied to the problem of brain tumor diagnosis. Such techniques still …

[HTML][HTML] Survival outcomes and prognostic factors in glioblastoma

NF Brown, D Ottaviani, J Tazare, J Gregson, N Kitchen… - Cancers, 2022 - mdpi.com
Simple Summary Glioblastoma is the most common tumour that originates in the brain in
adults. Most of the published data on glioblastoma are from patients in clinical trials who …